VINC vs. PTPI, BPTSY, HEPA, BPTH, BON, PBLA, SYRS, AMPE, NCNA, and ARDS
Should you be buying Vincerx Pharma stock or one of its competitors? The main competitors of Vincerx Pharma include Petros Pharmaceuticals (PTPI), Biophytis (BPTSY), Hepion Pharmaceuticals (HEPA), Bio-Path (BPTH), Bon Natural Life (BON), Panbela Therapeutics (PBLA), Syros Pharmaceuticals (SYRS), Ampio Pharmaceuticals (AMPE), NuCana (NCNA), and Aridis Pharmaceuticals (ARDS). These companies are all part of the "pharmaceutical products" industry.
Vincerx Pharma vs. Its Competitors
Vincerx Pharma (NASDAQ:VINC) and Petros Pharmaceuticals (NASDAQ:PTPI) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, institutional ownership, risk, profitability, analyst recommendations and dividends.
Petros Pharmaceuticals has higher revenue and earnings than Vincerx Pharma. Vincerx Pharma is trading at a lower price-to-earnings ratio than Petros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Vincerx Pharma currently has a consensus price target of $40.00, indicating a potential upside of 80,221.29%. Given Vincerx Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Vincerx Pharma is more favorable than Petros Pharmaceuticals.
In the previous week, Vincerx Pharma's average media sentiment score of 0.00 equaled Petros Pharmaceuticals'average media sentiment score.
44.0% of Vincerx Pharma shares are owned by institutional investors. Comparatively, 12.3% of Petros Pharmaceuticals shares are owned by institutional investors. 15.6% of Vincerx Pharma shares are owned by insiders. Comparatively, 12.3% of Petros Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Petros Pharmaceuticals' return on equity of -78.22% beat Vincerx Pharma's return on equity.
Vincerx Pharma has a beta of 1.7, meaning that its share price is 70% more volatile than the S&P 500. Comparatively, Petros Pharmaceuticals has a beta of 1.59, meaning that its share price is 59% more volatile than the S&P 500.
Summary
Vincerx Pharma beats Petros Pharmaceuticals on 8 of the 12 factors compared between the two stocks.
Get Vincerx Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for VINC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding VINC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vincerx Pharma Competitors List
Related Companies and Tools
This page (NASDAQ:VINC) was last updated on 9/29/2025 by MarketBeat.com Staff
Free VINC Stock Alerts